Currently, defeatHIV clinical studies are focused on treating HIV infected individuals who also suffer from hematologic malignancies such as leukemia or lymphoma. While today’s HIV therapy can often suppress the virus and minimize its effects on the body, the combination of HIV and cancer diagnoses has historically been difficult for clinicians to manage. The powerful drugs often required to treat blood cancers can exacerbate the HIV infection, ultimately making things worse for the patient. However, recent advances in hematopoietic cell transplantation (HCT) have demonstrated remarkable results in people suffering from HIV and cancers of the blood (see Berlin Patient). Our goal is to build on these successes and utilize our expertise in HIV virology, transplantation biology and genome editing technologies to develop a new therapeutic approach for eradicating HIV.
We hope this information will serve as a resource for patients, clinicians and other individuals interested in our clinical research efforts. Follow the link to our Clinical Studies page and learn more about these studies, eligibility criteria and clinic contact information.